MTOR and nonpapillary renal cell carcinoma: Retrospective studies on metastatic CCRCC patients indicate that PBRM1 loss is associated with improved outcomes in patients treated with either VEGFR TKIs or mTOR inhibitors, whereas BAP1 and TP53 mutations were associated with unfavorable cancer-specific outcomes [185].